Alirocumab Provides Additional Reduction of 75% in Standardized Rate of Apheresis Treatment
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
European Heart Journal
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia Undergoing Lipoprotein Apheresis: The ODYSSEY ESCAPE Trial
Eur Heart J 2016 Aug 29;[EPub Ahead of Print], PM Moriarty, KG Parhofer, SP Babirak, MA Cornier, PB Duell, B Hohenstein, J Leebmann, W Ramlow, V Schettler, V Simha, E Steinhagen-Thiessen, PD Thompson, A Vogt, B von Stritzky, Y Du, G ManvelianFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.